Liu, J., Zhang, H., Zhu, X., Chen, H., Li, X., & Ding, Y. (2021). Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors. Front Pharmacol.
Citação norma ChicagoLiu, Jingrui, Hong Zhang, Xiaoxue Zhu, Hong Chen, Xiaojiao Li, and Yanhua Ding. "Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors." Front Pharmacol 2021.
Citação norma MLALiu, Jingrui, et al. "Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors." Front Pharmacol 2021.